Transaction · 0001213900-26-098775

Shen Ethan PhD

Shen Ethan PhD, CEO, reported an open-market or private purchase at YD Bio Ltd involving 3100.000000 shares for an estimated $12183.00. Reported holdings after the transaction were 11245631.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market buySEC transaction code PCEO
YDESYD Bio Ltd
Trade date
Sep 09, 2026
Filing date
Sep 10, 2026
View on SEC Insider profile
Estimated value$12.1kShares × reported price
Shares traded3.10k$3.93 per share
Holdings after11.2MDirect
% of reported position traded0.03%This security and ownership context
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 11,242,531 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

YDES price since this filing

Daily closing prices, with the filing date and available return windows
YDES · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago +9.0%
Returns since7d -16.9%30d +72.6%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Buy
Code P
Identifier
0001213900-26-098775
Ordinary Shares
Transaction date
Sep 09, 2026
Filed Sep 10, 2026, 08:01 PM · 1d delay
Shares
3,100 sh
$3.93 per share
Estimated value
$12.1k
Computed from shares × price
Holdings after
11,245,631 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
CEO Buy Director Buy Direct Ownership
Filing-only score

+34 points

Compact filing score computed from stored Form 4 facts. Version v1.

Strong filing signal

This filing has a high positive filing-only score. It may deserve closer research, but it is not an investment recommendation.

How this score is calculated
  • open_market_purchase+12 points

    transaction_code = P

    Code P is a discretionary open-market purchase.
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • ceo_buy+12 points

    is_officer + officer_title/role mentions CEO

    CEO open-market purchase.
  • timely_filing+4 points

    reporting_delay_days = 1

    Filing reported within two business days of the transaction.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.80 to $4.09, inclusive. The reporting person undertakes to provide t…

  2. F2

    The reported shares are held by YD Biopharma Holding Limited, which is wholly owned by E820N Assets Ltd. (BVI), which is wholly owned by The E820N Trust (the "Trust"). Dr. Shen is the settlor, protect…

Original filing · 0001213900-26-098775
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

YDES